Vaccinating captive chimpanzees to save wild chimpanzees

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 24, 2014, Pages 8873-8876

  Warfield, Kelly L ^a   Goetzmann, Jason E ^b   Biggins, Julia E ^c   Kasda, Mary Beth ^c   Unfer, Robert C ^a   Vu, Hong ^a   Aman, M Javad ^a   Olinger Jr , Gene Gerrard ^c   Walsh, Peter D ^d  

^a Integrated BioTherapeutics Inc   (United States)

^b UNIVERSITY OF LOUISIANA AT LAFAYETTE   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Conservation; Filovirus; Wildlife disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; EBOLA VACCINE; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BLOOD CHEMISTRY; BODY MASS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMPANZEE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; ERYTHROCYTE; FEMALE; GORILLA; IMMUNOGENICITY; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RISK ASSESSMENT; SPECIES EXTINCTION; THROMBOCYTE; VACCINATION; WILD ANIMAL;

CONSERVATION; FILOVIRUS; WILDLIFE DISEASE;

ANIMALS; ANIMALS, WILD; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; CPG ISLANDS; DISEASE MODELS, ANIMAL; EBOLA VACCINES; ENDANGERED SPECIES; FEMALE; HEMORRHAGIC FEVER, EBOLA; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; PAN TROGLODYTES; VACCINATION;

EID: 84902593773     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1316902111     Document Type: Article

References (33)

1. Keele BF, et al. (2009) Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 460(7254):515-519.
2. Leendertz FH, et al. (2004) Anthrax kills wild chimpanzees in a tropical rainforest. Nature 430(6998):451-452. (Pubitemid 38987905)
3. Liu W, et al. (2010) Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature 467(7314):420-425.
4. Köndgen S, et al. (2008) Pandemic human viruses cause decline of endangered great apes. Curr Biol 18(4):260-264.
5. Williams JM, et al. (2008) Causes of death in the Kasekela chimpanzees of Gombe National Park, Tanzania. Am J Primatol 70(8):766-777.
6. Palacios G, et al. (2011) Human metapneumovirus infection in wild mountain gorillas, Rwanda. Emerg Infect Dis 17(4):711-713.
7. Walsh PD, et al. (2003) Catastrophic ape decline in western equatorial Africa. Nature 422(6932):611-614. (Pubitemid 36460413)
8. Bermejo M, et al. (2006) Ebola outbreak killed 5000 gorillas. Science 314(5805):1564. (Pubitemid 44907142)
9. Walsh PD, et al. (2007) in 2007 IUCN Red List of Threatened Species, (IUCN) Available at www.iucnredlist.org.
10. Ryan SJ, Walsh PD (2011) Consequences of non-intervention for infectious disease in African great apes. PLoS ONE 6(12):e29030.
11. Walsh PD (2012) in Key Topics in Conservation Biology, eds MacDonald DW, Willis KJ (Wiley, Hoboken), pp 452-466.
12. Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9(10):1149-1176.
13. Warfield KL, et al. (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196(Suppl 2):S430-S437. (Pubitemid 351417291)
14. Fisher-Hoch SP, et al. (1983) Haematological and biochemical monitoring of Ebola infection in Rhesus monkeys: Implications for patient management. Lancet 2(8358):1055-1058.
15. Sullivan NJ, Martin JE, Graham BS, Nabel GJ (2009) Correlates of protective immunity for Ebola vaccines: Implications for regulatory approval by the animal rule. Nat Rev Microbiol 7(5):393-400.
16. Wilson JA, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287(5458):1664-1666. (Pubitemid 30127770)
17. Olinger GG, Jr., et al. (2012) Delayed treatment of Ebola virus infection with plantderived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 109(44):18030-18035.
18. Olinger GG, et al. (2005) Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 79(22):14189-14196. (Pubitemid 41552717)
19. Zeitlin L, et al. (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci USA 108(51): 20690-20694.
20. Teng MN, et al. (2000) Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 74(19):9317-9321.
21. Institute of Medicine (2011) Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity (National Academies, Washington, DC).
22. National Institutes of Health (2012) Report of the Council of Councils Working Group on the Use of Chimpanzees in NIH-Supported Research. Available at http://dpcpsi.nih. gov/council/pdf/FNL-Report-WG-Chimpanzees.pdf. Accessed May 8, 2014.
23. US Fish and Wildlife Service (2013) Endangered and threatened wildlife and plants; Listing all chimpanzees as Endangered. Federal Register 78:35201-35217.22.
24. National Research Council (2011) Guide for the Care and Use of Laboratory Animals, 8th ed, (National Academies Press, Washington, DC).
25. Coler RN, et al. (2010) A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5(10):e13677.
26. Marshall JD, et al. (2003) Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells. Nucleic Acids Res 31(17):5122- 5133.
27. Warfield KL, et al. (2007) Filovirus-like particles produced in insect cells: Immunogenicity and protection in rodents. J Infect Dis 196(Suppl 2):S421-S429. (Pubitemid 351417290)
28. Lee JE, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454(7201):177-182. (Pubitemid 351969896)
29. Kallstrom G, et al. (2005) Analysis of Ebola virus and VLP release using an immunocapture assay. J Virol Methods 127(1):1-9. (Pubitemid 40704631)
30. Moe JB, Lambert RD, Lupton HW (1981) Plaque assay for Ebola virus. J Clin Microbiol 13(4):791-793. (Pubitemid 11047571)
31. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178(3): 651-661. (Pubitemid 28397211)
32. Sullivan NJ, et al. (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3(6):e177.
33. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812): 605 - 609.